益糖康调控内质网应激介导NLRP3炎症小体改善db/db小鼠小肠屏障损伤的作用机制研究OA
Study on Mechanism of Yitangkang in Ameliorating Intestinal Barrier Injury in db/db Mice by Regulating Endoplasmic Reticulum Stress-Mediated NLRP3 Inflammasome Activation
目的 探讨益糖康调控内质网应激介导NOD样受体热蛋白结构域相关蛋白3(NLRP3)炎症小体改善db/db小鼠小肠屏障损伤的作用机制.方法 采用随机数字表法将30只db/db小鼠分为模型组、益糖康组和利拉鲁肽组,每组10只,并设10只db/m小鼠为空白组,分别予相应药物干预5周后,检测小鼠空腹血糖(FBG)、空腹胰岛素(FINS)及稳态模型胰岛素抵抗指数(HOMA-IR)评估其代谢状态,HE染色观察小肠组织形态,电镜观察小肠上皮超微结构,免疫荧光法检测小肠组织闭锁小带蛋白-1(ZO-1)、闭合蛋白(Occludin)、封闭蛋白1(Claudin1)表达,Western blot检测小肠组织紧密连接、内质网应激、炎症小体及炎症因子相关蛋白表达.结果 与空白组比较,模型组小鼠各时点FBG明显升高(P<0.01),FINS、HOMA-IR明显升高(P<0.01);HE染色结果显示,小肠黏膜结构破坏,可见大量炎性细胞浸润与组织水肿,电镜结果显示,小肠黏膜上皮细胞间紧密连接间隙增宽;小肠组织ZO-1、Occludin、Claudin1蛋白表达明显降低(P<0.05,P<0.01),葡萄糖调节蛋白78(GRP78)、CCAAT增强子结合蛋白同源蛋白(CHOP)、NLRP3、凋亡相关斑点样蛋白(ASC)、cleaved Caspase-1、GSDMD-N、白细胞介素(IL)-1β、IL-18蛋白表达显著升高(P<0.01).与模型组比较,利拉鲁肽组小鼠给药1周后FBG明显降低(P<0.05,P<0.01),益糖康组小鼠给药2周后FBG明显降低(P<0.01),2组小鼠FINS、HOMA-IR均明显降低(P<0.01);HE染色结果显示,益糖康组和利拉鲁肽组小肠黏膜结构改善,炎症损伤减少,电镜结果显示,小肠黏膜上皮细胞间紧密连接结构致密,细胞间隙明显缩小;小肠组织ZO-1、Occludin、Claudin1蛋白表达明显升高(P<0.05,P<0.01),GRP78、CHOP、NLRP3、ASC、cleaved Caspase-1、GSDMD-N、IL-1β、IL-18蛋白表达明显降低(P<0.05,P<0.01).结论 益糖康可能通过抑制内质网应激减轻NLRP3炎症小体活化,改善db/db小鼠小肠炎症反应,从而修复糖尿病小肠屏障损伤.
Objective To investigate the mechanism of Yitangkang in ameliorating intestinal barrier injury in db/db mice by regulating endoplasmic reticulum stress(ERS)-mediated NLRP3 inflammasome activation.Methods Totally 30 db/db mice were divided into the model group,Yitakang group and liraglutide group according to random number table method,with 10 mice in each group.Another 10 db/m mice were set as the blank group.After 5 weeks of intervention,fasting blood glucose(FBG),fasting insulin(FINS)and homeostasis model assessment of insulin resistance(HOMA-IR)were measured to assess metabolic status,small intestinal histopathology was evaluated by HE staining,and ultrastructure of small intestinal epithelial cells were observed via electron microscope,the expressions of ZO-1,Occludin,Claudin1 were detected by immunofluorescence,Western blot was used to analyze the related proteins expression of tight junction,ERS,NLRP3 inflammasome and inflammatory cytokine.Results Compared with the blank group,the model group exhibited significantly increased FBG(P<0.01),serum FINS and HOMA-IR(P<0.01);HE staining revealed severe intestinal mucosal damage,inflammatory infiltration and tissue edema in the model group,electron microscope showed widened tight junctions between intestinal epithelial cells;the protein expressions of ZO-1,Occludin and Claudin1 were significantly decreased(P<0.05,P<0.01),while GRP78,CHOP,NLRP3,ASC,cleaved Caspase-1,GSDMD-N,IL-1β and IL-18 significantly increased(P<0.01).Compared with the model group,FBG in liraglutide group significantly decreased after 1 week of administration(P<0.05,P<0.01),FBG in Yitangkang group significantly decreased after 2 weeks of administration(P<0.01),FINS and HOMA-IR in both groups significantly decreased(P<0.01);the results of HE staining showed that the structure of small intestinal mucosa was improved and the inflammatory injury was reduced in Yitangkang group and liraglutide group,the electron microscope results showed that the tight junction structure between the epithelial cells of small intestinal mucosa was dense,and the intercellular space was significantly reduced;the protein expressions of ZO-1,Occludin and Claudin1 in small intestine significantly increased(P<0.05,P<0.01),while the protein expressions of GRP78,CHOP,NLRP3,ASC,cleaved Caspase-1,GSDMD-N,IL-1β and IL-18 significantly decreased(P<0.05,P<0.01).Conclusion Yitangkang may alleviate the activation of NLRP3 inflammasome by inhibiting ERS and improve the intestinal inflammatory response in dB/db mice,so as to repair the damage of diabetic intestinal barrier.
王诗怡;孙贵炎;张晖;杨宇峰;石岩
辽宁中医药大学,辽宁 沈阳 110847温州医科大学附属慈溪医院,浙江 宁波 315300辽宁中医药大学,辽宁 沈阳 110847辽宁中医药大学,辽宁 沈阳 110847辽宁中医药大学,辽宁 沈阳 110847
医药卫生
益糖康2型糖尿病内质网应激NOD样受体热蛋白结构域相关蛋白3小肠屏障损伤
Yitangkangtype 2 diabetes mellitusendoplasmic reticulum stressNLRP3intestinal barrier injury
《中国中医药信息杂志》 2026 (1)
77-83,7
国家中医药管理局青年岐黄学者项目(2022年)辽宁省应用基础研究计划(2023JH2/101300050)辽宁省"兴辽英才计划"青年拔尖人才项目(XLYC1807145)辽宁省科技计划联合计划自然科学基金-博士科研启动项目(2024-BSLH-152)宁波市卫生健康科技计划项目(2024Y66)
评论